Assessment of risk factors for retinal vein occlusions in patients under 60 years of age;Évaluation du bilan étiologique des occlusions veineuses rétiniennes du sujet âgé de moins de 60 ans

Journal Francais d'Ophtalmologie

Volumn 30, Issue 9, 2007, Pages 918-923

  Salaun, N ^a,b   Delyfer, M N ^a   Rougier, M B ^a   Korobelnik, J F ^a  

^a HÔPITAL PELLEGRIN   (France)

^b HÔPITAL D'INSTRUCTION DES ARMÉES ROBERT PICQUÉ   (France)

Author keywords

Hyperhomocysteinemia; Retinal vein occlusion; Thrombophilia

Indexed keywords

ADULT; ARTICLE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; INTRAOCULAR HYPERTENSION; MIDDLE AGED; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; HUMANS; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; MIDDLE AGED; OCULAR HYPERTENSION; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 37149027789     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(07)74029-9     Document Type: Article

References (47)

1. David R, Zangwill L, Badarna M, Yassur Y. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica, 1988;197:69-74.
2. Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol, 1993;37:393-417.
3. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol, 1996;114:545-54.
4. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology, 1983;90:458-74.
5. Hayreh SS, Hayreh MS. Hemi-central retinal vein occlusion. Pathogenesis, clinical features, and natural history. Arch Ophthalmol, 1980;98:1600-9.
6. Guilland JC, Favier A, Potier de Courcy G, Galan P, Hercberg S. L'hyperhomocystéinémie : facteur de risque cardiovasculaire ou simple marqueur ? Pathol Biol, 2003;51:101-10.
7. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med, 1999;131:363-75.
8. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med, 1991;324:1149-55.
9. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA, 1997;277:1775-81.
10. Lattanzio R, Sampietro F, Ramoni A, Fattorini A, Brancato R, D'Angelo A. Moderate hyperhomocysteinemia and early-onset central retinal vein occlusion. Retina, 2006;26:65-70.
11. Di Crecchio L, Parodi MB, Sanguinetti G, et al. Hyperhomocysteinemia and the methylenetetrahydrofolate reductase 677C-T mutation in patients under 50 years of age affected by central retinal vein occlusion. Ophthalmology, 2004;111:940-5.
12. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol, 2001;131:61-77.
13. Klein R, Klein BK, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Tr Am Ophthalmol Soc, 2000;98:133-43.
14. Sayag D, Gotzamanis A, Brugniart C, Segal A, Ducasse A, Chambre V, et al. Occlusion veineuse rétinienne et imagerie doppler carotidienne. J Fr Ophtalmol, 2002;25:826-30.
15. Rauh G, Fischereder M, Nasemann J, Muller M, Gruterich M, Spannagl M. Evaluation of atherosclerosis in patients with central retinal vein occlusion by carotid artery duplex scanning and echocardiography: a prospective case-control study. Eur J Med Res, 1996;25:429-32.
16. Hayreh SS, Zimmerman MB, Beri M, Podhajsky P. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. Ophthalmology, 2004;111:133-41.
17. Beaumont PE, Kang K. Cup-to-Disc Ratio, Intraocular pressure and primary open-angle glaucoma in retinal venous occlusion. Ophthalmology, 2002;109:282-6.
18. Janssen MCH, Den Heijer M, Cruysberg JRM, Wollersheim H, Bredie SJH. Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost, 2005;93:1021-6.
19. Marcucci R, Bertini L, Giusti B, Brunelli T, Fedi S, Cellai A, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost, 2001;86:772-6.
20. Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr, 1998;157(Suppl 2):40-4.
21. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest, 1993;91:308-18.
22. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest, 1976;58:731-41.
23. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med, 1991;324:1149-55.
24. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA, 1997;277:1775-81.
25. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med, 1999;131:363-75.
26. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease causal or casual? Arch Intern Med, 2000;160:422-34.
27. Brown BA, Marx JL, Ward TP, Hollifield RD, Dick JS, Brozetti JJ, et al. Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology, 2002;109:287-90.
28. Vine AK. Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol, 2000;129:640-4.
29. Weger M, Stanger O, Deutschmann H, Temmel W, Renner W, Schmut O, et al. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol, 2002;240:286-90.
30. Lahey JM, Tunc M, Kearney J, Modlinski B, Koo H, Johnson RN, et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology, 2002;109:126-31.
31. McGimpsey SJ, Woodside JV, Bamford L, Gilchrist SE, Graydon R, Mc Keeman GC, et al. Retinal vein occlusion, homocysteine, and methylene tetrahydrofolate reductase genotype. Invest Ophthalmol Vis Sci, 2005;46:4712-5.
32. Van de Laak MF, Grobbee DE, Van der Griend R, De Valk HW, Algra A, Banga JD, et al. A 2-step strategy to reduce the need for methionine loading tests to diagnose hyperhomocysteinemia. J Lab Clin Med, 2003;142:121-7.
33. Marongiu F, Fenu M, Pisu G, Contu P, Barcellona D. Hyperhomocysteinemia: could the post-methionine oral loading test sometimes be avoided? Haematologica, 2003;88:186-91.
34. Marcucci R, Giusti B, Betti I, Evangelisti L, Fedi S, Sodi A, et al. Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. Thromb Res, 2003;110:7-12.
35. Chak M, Wallace GR, Graham EM, Stanford MR. Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease. Br J Ophthalmol, 2001;85:883-6.
36. Weger M, Renner W, Steinbrugger I, Cichocki L, Temmel W, Stanger O, et al. Role of thrombophilic gene polymorphisms in branch retinal vein occlusion. Ophthalmology, 2005;112:1910-5.
37. Larsson J, Olafsdottir E, Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol, 1996;80:200-2.
38. Gottlieb JL, Blice JP, Mestichelli B, Konkle BA, Benson WE. Activated Protein C Resistance, Factor V Leiden, and central retinal vein occlusion in young adults. Arch Ophthalmol, 1998;116:577-9.
39. Freyburger G, Bilhou-Nabera C, Dief S, Javorschi S, Labrouche S, Lerebeller MJ, et al. Technical and biological conditions influencing the functional APC resistance test. Thromb Haemost, 1996;75:460-5.
40. Raguenes O, Mercier B, Escoffre M, Traore L, Blouch MT, Robinet A, et al. G to A mutation of the factor V gene: no association with thrombosis of the central retinal vein. Presse Med, 1996;25:460.
41. Cobo-Soriano R, Sanchez-Ramon S, Aparicio MJ, Teijeiro MA, Vidal P, Suarez-Leoz M, et al. Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. Am J Ophthalmol, 1999;128:725-32.
42. Bashshur ZF, Taher A, Masri AF, Najjar D, Arayssi TK, Noureddin BN. Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors: a prospective study. Retina, 2003;23:486-90.
43. Behbehani R, Sergott RC, Savino PJ. The antiphospholipid antibody syndrome: diagnostic aspects. Curr Opin Ophthalmol, 2004;15:483-5.
44. Ilhan F, Celiker U, Godekmerdan A, Kan E. The antiphospholipid antibody syndrome research in patients with retinal venous occlusion. Arch Med Res, 2005;36:372-5.
45. Paccalin M, Manic H, Bouche G, Landron C, Mercie M, Boinot C, et al. Antiphospholipid syndrome in patients with retinal venous occlusion. Thromb Res, 2006;117:365-9.
46. Abu El-Asrar AM, Abdel Gader AG, Al-Amro S, Al-Momem AK. Fibrinolytic activity in retinal vein occlusion. Int Ophthalmol, 1997-98;21:343-8.
47. Kadayifçilar S, Özatli D, Özcebe OI, Sqener EC. Is activated factor VII associated with retinal vein occlusion? Br J Ophthalmol, 2001;85:1174-8.